FimmCyte and Richter Collaborate on Endometriosis Breakthrough – Startupticker.ch
Startupticker.ch shared a post on LinkedIn։
“FimmCyte, a femtech company developing new treatments for endometriosis, has entered into a research collaboration and option-to-license agreement with Richter, a leading Hungarian pharmaceutical company, to advance research on its lead clinical candidate, FMC2. The parties have fully negotiated a definitive, exclusive and worldwide license agreement for the future development and commercialization of the antibody. FimmCyte will be eligible to receive development and commercial milestone payments, together with tiered royalties on net sales, as provided under the pre-agreed license agreement.
More about FimmCyte, its clinical candidate and the collaboration in our article․”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Mar 12, 2026, 14:29Fahima Hussain: When Reproductive Trauma Goes Unspoken
-
Mar 12, 2026, 12:56Vinnie Arvin Amir: New AI Study Explores Immune Factors in Pregnancy Loss
-
Mar 12, 2026, 12:53Deep Learning Bridges the Diagnostic Gap in Chronic Endometritis – Medicina MDPI
-
Mar 12, 2026, 12:49Explore the ASRM CELL Training Lab – ASRM
-
Mar 12, 2026, 02:28Anthony Griffiths to Discuss Multidisciplinary Approaches to Endometriosis Care – BSGI
-
Mar 11, 2026, 12:36Christopher Robinson: B-Lynch Uterine Compression Technique Discussed in AJOG Expert Review
-
Mar 11, 2026, 09:55Abstract Deadline and Early Registration Approaching for ESHRE Embryology 2026 – ESHRE
-
Mar 11, 2026, 08:57How Hyaluronic Acid Medium Improves Live Birth Rate? – RBMO
-
Mar 11, 2026, 08:46PCOS and Higher BMI Linked to Increased Risk of Type 2 Diabetes – Fertility and Sterility